Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma
No Thumbnail Available
Date
2019
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer Medknow Publications
Access Rights
info:eu-repo/semantics/openAccess
Abstract
Objective: To determine the prognostic value of excision repairs cross-complementation group1 (ERCC1) gene in cases with nasopharyngeal carcinoma (NPC) treated with platinum-containing chemotherapy (PCT). Subjects and Methods: The present study was included 33 cases in local advanced stage with NPC. ERCC1 expression was evaluated by using immunohistochemical staining in biopsy specimens. We evaluated the relationship between the degree of ERCC1 expression and clinicopathological features, response to therapy, survival rates in cases with NPC, retrospectively. Results: ERCC1 expression was not observed in 5 (15.15%) of all cases. Thirteen (39.9%) cases weakly positive (+1, +2) and 15 (45.5%) cases of all them were rather strongly positive (+3). There was no statistically significant difference between the degree of ERCC1 expression and clinicopathological features, response to treatment, survival rates (P 0.05) in cases with NPC. Conclusions: ERCC1 expression has no predictive value for survival in cases locally advanced stage with NPC. Evaluation of ERCC1 expression is not appropriate with a biomarker to detect cases who can benefit from PCT in NPC.
Description
Keywords
Excision repair cross-complementation group1, nasopharyngeal carcinoma, platinum resistance, survival
Journal or Series
Journal of Cancer Research and Therapeutics
WoS Q Value
Q4
Scopus Q Value
Q3
Volume
15
Issue
3
